SEATTLE--(BUSINESS WIRE)--Northstar Neuroscience, Inc., (NASDAQ:NSTR), a medical device company developing therapies for the treatment of neurological diseases and disorders, today announced financial results for its third quarter ended September 30, 2007. Continued investments in the Company’s clinical programs, including the EVEREST pivotal trial for stroke motor recovery (a), and development of the RenovaTM Cortical Stimulation System, resulted in a net loss of $5.4 million, or $0.21 per share, for the third quarter of 2007, compared to an equivalent net loss for the third quarter of the prior year of $5.4 million, or $0.21 per share. Northstar also reported cash and investments of $88.6 million at September 30, 2007 compared to $105.3 million at December 31, 2006.
